22 February 2022 in The Breast
Cyclin-Dependent Kinase (CDK) 4/6 inhibitors have shown significant clinical activity in cancer patients. However, some concerns regarding rare adverse events (AEs) have occurred including interstitial lung disease (ILD)/pneumonitis, for which data are deficient. The aim of this study was to evaluate the overall incidence and risk of ILD/pneumonitis related to CDK4/6 inhibitors in randomized controlled trials (RCTs). Electronic databases and ClinicalTrials.gov were searched from inception to October 1, 2021 for RCTs reporting the occurrence of LD/pneumonitis in cancer patients treated with CDK4/6 inhibitors. Peto odds ratios (Peto ORs) and 95% confidence intervals (CIs) were used to pool the study. 12 RCTs with a total of 16,060 patients were eligible. The overall incidence of all-grade ILD/pneumonitis was 1.6% (131/8407) in the treatment group compared with 0.7% (50/7349) in the control group. CDK4/6 inhibitors significantly increased the risk of all-grade ILD/pneumonitis with a pooled Peto OR of 2.12 (95% CI [1.57, 2.86], P < 0.00001) with no heterogeneity (I2 = 0%, χ2 P = 0.98). A higher incidence of grade 3 or higher ILD/pneumonitis was also observed in the treatment group (0.2%, 16/7087) compared with the control group (0.05%, 3/6617) with a Peto OR of 3.22 (95% CI [1.28, 8.09], P = 0.01) with no heterogeneity (I2 = 0%, χ2 P = 0.62). Two grade 5 pneumonitis were reported in the included studies. Subgroup analyses did not show any significant difference. The risk of all-grade and grade 3 or higher ILD/pneumonitis was higher in patients treated with CDK4/6 inhibitors compared to controls. The awareness for these rare AEs in the application of CDK4/6 inhibitors should be enhanced. Further studies are required to validate the mechanisms and the risk factors of ILD/pneumonitis with CDK4/6 inhibitors.
11 February 2017 in Proceedings of the AAAI Conference on Artificial Intelligence
In this paper, we recast the subspace clustering as a verification problem. Our idea comes from an assumption that the distribution between a given sample x and cluster centers Omega is invariant to different distance metrics on the manifold, where each distribution is defined as a probability map (i.e. soft-assignment) between x and Omega. To verify this so-called invariance of distribution, we propose a deep learning based subspace clustering method which simultaneously learns a compact representation using a neural network and a clustering assignment by minimizing the discrepancy between pair-wise sample-centers distributions. To the best of our knowledge, this is the first work to reformulate clustering as a verification problem. Moreover, the proposed method is also one of the first several cascade clustering models which jointly learn representation and clustering in end-to-end manner. Extensive experimental results show the effectiveness of our algorithm comparing with 11 state-of-the-art clustering approaches on four data sets regarding to four evaluation metrics.
13 January 2009 in IEEE Transactions on Neural Networks
A continuous attractor of a recurrent neural network (RNN) is a set of connected stable equilibrium points. Continuous attractors have been used to describe the encoding of continuous stimuli in neural networks. Dynamic behaviors of continuous attractors of RNNs exhibit interesting properties. This brief desires to derive explicit representations of continuous attractors of RNNs. Representations of continuous attractors of linear RNNs as well as linear-threshold (LT) RNNs are obtained under some conditions. These representations could be looked at as solutions of continuous attractors of the networks. Such results provide clear and complete descriptions to the continuous attractors.
16 September 2022 in Expert Review of Clinical Pharmacology
Interstitial lung disease (ILD) events associated with anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugates (ADCs) have aroused wide attention.In meta-analysis, we systemat...
21 May 2025 in Expert Opinion on Drug Safety
Angiogenesis inhibitors are associated with increased risk of thromboembolic events (TEEs) and hemorrhagic events. However, their clinical features are not well characterized in real-world studies. First, we conducted a pharmacovigilance study to investigate characteristics of TEEs and bleeding and compare vascular endothelial growth factor and its receptor inhibitors (VEGF/VEGFRIs) with other antiangiogenic agents. Second, we performed a retrospective analysis of lung cancer patients who received bevacizumab or anlotinib to assess the incidence of VEGF/VEGFRI-associated TEEs and bleeding. In the pharmacovigilance study, both VEGF/VEGFR-targeted biologics and VEGFR-tyrosine kinase inhibitors were associated with higher reporting of arterial thromboembolism (ATE) (reporting odd ratio (ROR) 2.91; ROR 1.25; respectively), and bleeding (ROR 2.56; ROR 2.35; respectively). Venous thromboembolism (VTE) was only associated with VEGF/VEGFR-targeted biologics (ROR 3.11). In the cohort study, bevacizumab, aflibercept, and ramucirumab showed the strongest associations with VTE, ATE, and bleeding, respectively. In the cohort study of 261 lung cancer patients treated with bevacizumab or anlotinib, 42.9% were older than 65 years, 62.1% were male, with TEEs occurred in 11.5%, and bleeding in 8.8%. All VEGF/VEGFRIs were associated with increased ATE and bleeding risk. VEGF/VEGFR-targeted biologics also significantly raise the risk of VTE.
20 February 2024 in Expert Opinion on Drug Safety
Anticancer drug-induced interstitial lung disease (DIILD) has received increasing clinical attention, and the quality of relevant guidance documents has become critical. Our purpose was to assess the quality of documents for anticancer DIILD and summarize the recommendations. Clinical practice guidelines (CPGs) and consensus statements with recommendations for the evaluation, treatment, and monitoring of anticancer DIILD were searched in electronic databases, websites of guideline organizations, and professional societies. The quality of documents was assessed using the Appraisal of Guidelines for Research & Evaluation II (AGREE II) methodology, and the specific recommendations were aggregated and compared to analyze the consistency among documents. A total of 11 documents were eligible, including 6 CPGs and 5 consensus statements. The quality of AGREE II assessments differed greatly, both between domains of documents and between documents across domains. The domains of scope and purpose and clarity of presentation received the highest median scores, while the stakeholder involvement domain received the lowest score. Recommendations were inconsistent between documents, particularly regarding the selection of steroid regimens. The methodological quality of the guidance documents needs to be enhanced, especially in the domain of stakeholder involvement. Inconsistencies exist in documents regarding specific recommendations for evaluation, treatment and, monitoring of anticancer DIILD, and further discussions among multidisciplinary experts are needed to reach an agreement. In particular, we have focused our concerns on the differences in steroid regimens, and future research is still needed on the risks of adverse events related to hormone therapy and discovery of precise biomarkers.